In recent years, the pharmaceutical landscape has seen a staggering 600% increase in the number of adolescents and young adults being prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist. According to data from pharmacy records, the number of individuals aged 12 to 25 receiving prescriptions for these medications skyrocketed from 8,722 to 60,567 per month between